Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iSpecimen (ISPC) Change in Account Payables: 2020-2025

Historic Change in Account Payables for iSpecimen (ISPC) over the last 5 years, with Sep 2025 value amounting to $456,016.

  • iSpecimen's Change in Account Payables rose 403.93% to $456,016 in Q3 2025 from the same period last year, while for Sep 2025 it was $715,694, marking a year-over-year decrease of 59.68%. This contributed to the annual value of $272,123 for FY2024, which is 81.44% down from last year.
  • Per iSpecimen's latest filing, its Change in Account Payables stood at $456,016 for Q3 2025, which was down 13.78% from $528,876 recorded in Q2 2025.
  • Over the past 5 years, iSpecimen's Change in Account Payables peaked at $1.6 million during Q4 2023, and registered a low of -$2.9 million during Q3 2021.
  • Over the past 3 years, iSpecimen's median Change in Account Payables value was $242,172 (recorded in 2023), while the average stood at $210,178.
  • Per our database at Business Quant, iSpecimen's Change in Account Payables tumbled by 978.44% in 2021 and then skyrocketed by 403.93% in 2025.
  • Quarterly analysis of 5 years shows iSpecimen's Change in Account Payables stood at $481,254 in 2021, then spiked by 209.88% to $1.5 million in 2022, then climbed by 10.32% to $1.6 million in 2023, then crashed by 91.36% to $142,229 in 2024, then surged by 403.93% to $456,016 in 2025.
  • Its Change in Account Payables was $456,016 in Q3 2025, compared to $528,876 in Q2 2025 and -$411,427 in Q1 2025.